Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00853385




Registration number
NCT00853385
Ethics application status
Date submitted
27/02/2009
Date registered
2/03/2009
Date last updated
18/01/2013

Titles & IDs
Public title
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Scientific title
Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Secondary ID [1] 0 0
A3921064
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CP 690,550
Treatment: Drugs - CP-690,550
Other interventions - Placebo
Other interventions - Placebo
Treatment: Other - Biologic TNFi

Experimental: 5mg -

Experimental: 10 mg -

Placebo comparator: Placebo Sequence 1 -

Placebo comparator: Placebo Sequence 2 -

Active comparator: adalimumab -


Treatment: Drugs: CP 690,550
tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months

Treatment: Drugs: CP-690,550
tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months

Other interventions: Placebo
placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

Other interventions: Placebo
tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

Treatment: Other: Biologic TNFi
placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Intervention code [3] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6
Timepoint [1] 0 0
Month 6
Primary outcome [2] 0 0
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3
Timepoint [2] 0 0
Baseline, Month 3
Primary outcome [3] 0 0
Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6
Timepoint [3] 0 0
Month 6
Secondary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3
Timepoint [1] 0 0
Month 1, 3
Secondary outcome [2] 0 0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12
Timepoint [2] 0 0
Month 9, 12
Secondary outcome [3] 0 0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6
Timepoint [3] 0 0
Month 1, 3, 6
Secondary outcome [4] 0 0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12
Timepoint [4] 0 0
Month 9, 12
Secondary outcome [5] 0 0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6
Timepoint [5] 0 0
Month 1, 3, 6
Secondary outcome [6] 0 0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12
Timepoint [6] 0 0
Month 9, 12
Secondary outcome [7] 0 0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6
Timepoint [7] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [8] 0 0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12
Timepoint [8] 0 0
Month 9, 12
Secondary outcome [9] 0 0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6
Timepoint [9] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [10] 0 0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12
Timepoint [10] 0 0
Month 9, 12
Secondary outcome [11] 0 0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])
Timepoint [11] 0 0
Baseline, Month 1, 3, 6, 9, 12
Secondary outcome [12] 0 0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])
Timepoint [12] 0 0
Baseline, Month 1, 3, 6, 9, 12
Secondary outcome [13] 0 0
Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6
Timepoint [13] 0 0
Month 1, 3, 6
Secondary outcome [14] 0 0
Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12
Timepoint [14] 0 0
Month 9, 12
Secondary outcome [15] 0 0
Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6
Timepoint [15] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [16] 0 0
Patient Assessment of Arthritis Pain at Month 9 and 12
Timepoint [16] 0 0
Month 9, 12
Secondary outcome [17] 0 0
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6
Timepoint [17] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [18] 0 0
Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12
Timepoint [18] 0 0
Month 9, 12
Secondary outcome [19] 0 0
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6
Timepoint [19] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [20] 0 0
Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12
Timepoint [20] 0 0
Month 9, 12
Secondary outcome [21] 0 0
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6
Timepoint [21] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [22] 0 0
36-Item Short-Form Health Survey (SF-36) at Month 9 and 12
Timepoint [22] 0 0
Month 9, 12
Secondary outcome [23] 0 0
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6
Timepoint [23] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [24] 0 0
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12
Timepoint [24] 0 0
Month 12
Secondary outcome [25] 0 0
Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6
Timepoint [25] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [26] 0 0
Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12
Timepoint [26] 0 0
Month 12
Secondary outcome [27] 0 0
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6
Timepoint [27] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [28] 0 0
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12
Timepoint [28] 0 0
Month 12
Secondary outcome [29] 0 0
Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6
Timepoint [29] 0 0
Baseline, Month 1, 3, 6
Secondary outcome [30] 0 0
Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12
Timepoint [30] 0 0
Month 12
Secondary outcome [31] 0 0
Work Limitations Questionnaire (WLQ) Score at Month 3 and 6
Timepoint [31] 0 0
Month 3, 6
Secondary outcome [32] 0 0
Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12
Timepoint [32] 0 0
Baseline, Month 12
Secondary outcome [33] 0 0
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6
Timepoint [33] 0 0
Baseline, Month 3, 6
Secondary outcome [34] 0 0
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12
Timepoint [34] 0 0
Month 12
Secondary outcome [35] 0 0
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Timepoint [35] 0 0
Baseline, Month 3, 6
Secondary outcome [36] 0 0
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12
Timepoint [36] 0 0
Month 12
Secondary outcome [37] 0 0
Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Timepoint [37] 0 0
Baseline, Month 3, 6
Secondary outcome [38] 0 0
Number of Days as Assessed Using RA-HCRU at Month 12
Timepoint [38] 0 0
Month 12
Secondary outcome [39] 0 0
Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6
Timepoint [39] 0 0
Baseline, Month 3, 6
Secondary outcome [40] 0 0
Number of Hours Per Day as Assessed RA-HCRU at Month 12
Timepoint [40] 0 0
Month 12
Secondary outcome [41] 0 0
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Timepoint [41] 0 0
Baseline, Month 3, 6
Secondary outcome [42] 0 0
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12
Timepoint [42] 0 0
Month 12

Eligibility
Key inclusion criteria
* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
* The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: =6 joints tender or painful on motion; and =6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) >28 mm in the local laboratory. 2. CRP >7 mg/L in the central laboratory.
* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
* The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Blood dyscrasias including confirmed: 1. Hemoglobin <9 g/dL or Hematocrit <30%; 2. White blood cell count <3,000 cu.mm. Absolute neutrophil count <1,200 cu.mm; 4. Platelet count <100,000/L
* History of any other autoimmune rheumatic disease other than Sjogren's syndrome
* No malignancy or history of malignancy.
* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
* Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.
* Patients who have previously received adalimumab therapy for any reason.
* Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.
* Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2011
Sample size
Target
Accrual to date
Final
717
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Pfizer Investigational Site - St Leonards
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Cairns
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Maroochydore
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Malvern East
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
4870 - Cairns
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
3145 - Malvern East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oklahoma
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
United States of America
State/province [19] 0 0
West Virginia
Country [20] 0 0
Bosnia and Herzegovina
State/province [20] 0 0
Sarajevo
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sevlievo
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Nova Scotia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Canada
State/province [29] 0 0
Saskatchewan
Country [30] 0 0
Chile
State/province [30] 0 0
RM
Country [31] 0 0
Chile
State/province [31] 0 0
Santiago, RM
Country [32] 0 0
Chile
State/province [32] 0 0
VI Region
Country [33] 0 0
Costa Rica
State/province [33] 0 0
Cartago
Country [34] 0 0
Costa Rica
State/province [34] 0 0
San Jose
Country [35] 0 0
Croatia
State/province [35] 0 0
Osijek
Country [36] 0 0
Croatia
State/province [36] 0 0
Split
Country [37] 0 0
Croatia
State/province [37] 0 0
Zagreb
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Brno - Zidenice
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Brno
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Hlucin
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Pardubice
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Praha 11 - Chodov
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Praha 11
Country [44] 0 0
Czech Republic
State/province [44] 0 0
Praha 2
Country [45] 0 0
Czech Republic
State/province [45] 0 0
Praha 4
Country [46] 0 0
Czech Republic
State/province [46] 0 0
Zlin
Country [47] 0 0
Denmark
State/province [47] 0 0
Frederiksberg
Country [48] 0 0
Denmark
State/province [48] 0 0
Randers NOE
Country [49] 0 0
Dominican Republic
State/province [49] 0 0
Santo Domingo
Country [50] 0 0
Finland
State/province [50] 0 0
Hyvinkaa
Country [51] 0 0
Germany
State/province [51] 0 0
Aachen
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Frankfurt am Main
Country [54] 0 0
Germany
State/province [54] 0 0
Halle
Country [55] 0 0
Germany
State/province [55] 0 0
Herne
Country [56] 0 0
Germany
State/province [56] 0 0
Ratingen
Country [57] 0 0
Germany
State/province [57] 0 0
Wuerzburg
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Daegu
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Gwangju
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Mexico
State/province [61] 0 0
DF
Country [62] 0 0
Mexico
State/province [62] 0 0
Jalisco
Country [63] 0 0
Mexico
State/province [63] 0 0
Michoacan
Country [64] 0 0
Mexico
State/province [64] 0 0
SLP
Country [65] 0 0
Philippines
State/province [65] 0 0
Batangas
Country [66] 0 0
Philippines
State/province [66] 0 0
Pampanga
Country [67] 0 0
Philippines
State/province [67] 0 0
Cebu City
Country [68] 0 0
Poland
State/province [68] 0 0
Bialystok
Country [69] 0 0
Poland
State/province [69] 0 0
Cieszyn
Country [70] 0 0
Poland
State/province [70] 0 0
Koscian
Country [71] 0 0
Poland
State/province [71] 0 0
Krakow
Country [72] 0 0
Poland
State/province [72] 0 0
Sopot
Country [73] 0 0
Poland
State/province [73] 0 0
Torun
Country [74] 0 0
Poland
State/province [74] 0 0
Warszawa
Country [75] 0 0
Slovakia
State/province [75] 0 0
Bratislava
Country [76] 0 0
Slovakia
State/province [76] 0 0
Dunajska Streda
Country [77] 0 0
Slovakia
State/province [77] 0 0
Kosice
Country [78] 0 0
Slovakia
State/province [78] 0 0
Nove Zamky
Country [79] 0 0
Slovakia
State/province [79] 0 0
Povazska Dystrica
Country [80] 0 0
Slovakia
State/province [80] 0 0
Zilina
Country [81] 0 0
Spain
State/province [81] 0 0
A Coruña
Country [82] 0 0
Spain
State/province [82] 0 0
Pontevedra
Country [83] 0 0
Spain
State/province [83] 0 0
Madrid
Country [84] 0 0
Spain
State/province [84] 0 0
Sevilla
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
Thailand
State/province [86] 0 0
Bangkok
Country [87] 0 0
Thailand
State/province [87] 0 0
Chiang Mai
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Merseyside
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Staffs
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Dudley, West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.
Trial website
https://clinicaltrials.gov/study/NCT00853385
Trial related presentations / publications
Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.
Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis Res Ther. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.
Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.
Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Adv Ther. 2021 Dec;38(12):5649-5661. doi: 10.1007/s12325-021-01930-4. Epub 2021 Oct 12.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, Germino R, Murray CW. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Res Ther. 2020 Oct 15;22(1):243. doi: 10.1186/s13075-020-02324-7.
Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z.
Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006. Epub 2018 Jul 19.
Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatol Ther. 2018 Dec;5(2):383-401. doi: 10.1007/s40744-018-0118-2. Epub 2018 Jun 11.
van Vollenhoven RF, Lee EB, Fallon L, Zwillich SH, Wilkinson B, Chapman D, DeMasi R, Keystone E. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. Arthritis Care Res (Hoboken). 2019 Jan;71(1):71-79. doi: 10.1002/acr.23585.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
Genovese MC, van Vollenhoven RF, Wilkinson B, Wang L, Zwillich SH, Gruben D, Biswas P, Riese R, Takiya L, Jones TV. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther. 2016 Jun 23;18:145. doi: 10.1186/s13075-016-1049-3.
Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14. Erratum In: Ann Rheum Dis. 2017 Mar;76(3):611. doi: 10.1136/annrheumdis-2014-207178corr1.
Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. Erratum In: N Engl J Med. 2013 Jul 18;369(3):293.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00853385